Neurocrine Biosciences NBIX Income Statement
| TTM Q1 '26 | TTM Q4 '25 | TTM Q3 '25 | TTM Q2 '25 | TTM Q1 '25 | ||
|---|---|---|---|---|---|---|
| $3.1B+8.5% | $2.86B+6.6% | $2.68B+6.9% | $2.51B+4.0% | $2.41B+2.4% | ||
| $56.7M+8.8% | $52.1M+18.9% | $43.8M+15.9% | $37.8M+5.9% | $35.7M+5.0% | ||
| $3.05B+8.4% | $2.81B+6.4% | $2.64B+6.7% | $2.47B+4.0% | $2.38B+2.4% | ||
| 98.2%0.0pp | 98.2%-0.2pp | 98.4%-0.1pp | 98.5%0.0pp | 98.5%0.0pp | ||
| $1.05B+3.2% | $1.02B+7.7% | $943.1M+6.2% | $888.1M+6.4% | $834.9M+14.2% | ||
| $1.2B+3.6% | $1.16B+1.2% | $1.14B+5.3% | $1.08B+4.3% | $1.04B+3.3% | ||
| $2.31B+3.2% | $2.24B+5.1% | $2.13B+5.8% | $2.01B+5.1% | $1.92B+7.5% | ||
| $788.9M+27.4% | $619.1M+12.5% | $550.2M+11.2% | $495M0.0% | $494.8M-13.3% | ||
| 25.4%+3.8pp | 21.6%+1.1pp | 20.5%+0.8pp | 19.7%-0.8pp | 20.5%-3.7pp | ||
| $148.6M+72.2% | $86.3M— | —— | —— | —— | ||
| —— | —— | —— | —— | —— | ||
| $937.5M+32.9% | $705.4M+12.2% | $628.6M+19.3% | $527.1M+13.1% | $466.2M-4.1% | ||
| $268.9M+18.6% | $226.8M+13.1% | $200.6M+12.2% | $178.8M+11.5% | $160.4M+10.9% | ||
| $668.6M+39.7% | $478.6M+11.8% | $428M+22.9% | $348.3M+13.9% | $305.8M-10.4% | ||
| 21.6%+4.8pp | 16.7%+0.8pp | 16%+2.1pp | 13.9%+1.2pp | 12.7%-1.8pp | ||
| $6.49+39.3% | $4.66+11.5% | $4.18+23.7% | $3.38+14.6% | $2.95-10.3% | ||
| $6.71+39.2% | $4.82+11.8% | $4.31+23.9% | $3.48+14.9% | $3.03-10.4% | ||
| 409.4M+0.2% | 408.5M-0.3% | 409.7M-0.4% | 411.5M-0.7% | 414.4M-0.3% | ||
| 398.4M+0.2% | 397.6M-0.2% | 398.5M-0.4% | 400.2M-0.4% | 402M0.0% | ||
| —— | —— | -$8.6M+84.7% | -$56.1M+19.0% | -$69.3M-86.8% | ||
| $96.7M+7.1% | $90.3M+3.8% | $87M-1.4% | $88.2M-2.4% | $90.4M-0.7% | ||
| $660M+35.8% | $485.9M+13.9% | $426.7M+19.1% | $358.3M+15.0% | $311.5M-8.4% | ||
| $26.6M+2.3% | $26M+0.8% | $25.8M+4.5% | $24.7M-0.4% | $24.8M+5.5% | ||
| —— | —— | —— | —— | —— | ||
| $81.1M-0.4% | $81.4M-44.5% | $146.6M-25.7% | $197.2M-9.5% | $217.9M+0.2% | ||
| $148.9M-7.1% | $160.2M-0.5% | $161M+7.8% | $149.4M+153% | $59M+35.9% | ||
| —— | —— | $248.9M+92.2% | $129.5M+92.1% | $67.4M+61.2% | ||
| $9.3M-39.2% | $15.3M-34.9% | $23.5M+62.1% | $14.5M-33.8% | $21.9M+14.7% | ||
| -$10.9M-411% | $3.5M+319% | -$1.6M-119% | $8.4M+75.0% | $4.8M+4,900% | ||
| $34.8M-4.4% | $36.4M-16.7% | $43.7M+13.2% | $38.6M+2.4% | $37.7M-1.3% | ||
| $120.9M-6.6% | $129.4M+26.7% | $102.1M+23.2% | $82.9M-1.7% | $84.3M-31.0% | ||
| $38.5M+121% | $17.4M+412% | $3.4M-17.1% | $4.1M-37.9% | $6.6M-47.2% | ||
| $1.05B+3.2% | $1.02B+7.7% | $943.1M+6.2% | $888.1M+6.4% | $834.9M+14.2% | ||
| $3.1B+8.5% | $2.86B+6.6% | $2.68B+6.9% | $2.51B+4.0% | $2.41B+2.4% | ||
| $222.3M+2.0% | $217.9M-3.5% | $225.7M+5.7% | $213.5M+4.8% | $203.8M+4.2% | ||
| $818.7M+26.1% | $649.2M+12.0% | $579.9M+10.8% | $523.5M0.0% | $523.3M-12.4% | ||
| 26.4%+3.7pp | 22.7%+1.1pp | 21.6%+0.8pp | 20.9%-0.8pp | 21.7%-3.7pp | ||
| $788.9M+27.4% | $619.1M+12.5% | $550.2M+11.2% | $495M0.0% | $494.8M-13.3% |
Chart any of these lines over time, or line them up against competitors.
Compare these in charts →Questions, answered.
- What is Neurocrine Biosciences's revenue?
- Neurocrine Biosciences (NBIX) generated $3.1B in revenue over the trailing twelve months, up 28.6% year over year.
- Is Neurocrine Biosciences profitable?
- Neurocrine Biosciences reported $668.6M in net income over the trailing twelve months, a 21.6% net margin.
- What are Neurocrine Biosciences's profit margins?
- Gross margin is 98.2% and operating margin is 25.4%, with a 21.6% net margin.
- What is Neurocrine Biosciences's earnings per share?
- Neurocrine Biosciences's diluted EPS over the trailing twelve months is $6.49.
- Where does Neurocrine Biosciences's income statement data come from?
- Every line is extracted from Neurocrine Biosciences's SEC filings (10-K and 10-Q) and tagged in XBRL. Switch between quarterly, annual, and trailing-twelve-month views, or open any line for its full history and peer comparisons.
